IO Biotech Inc (IOBT)vsRevolution Medicines Inc (RVMD)
IOBT
IO Biotech Inc
$0.05
0.00%
HEALTHCARE · Cap: $2.32M
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
IOBT
Avoid21
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IOBT
IOBT has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IOBT
The primary concerns for IOBT are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
IOBT is growing revenue faster at 0.0% — sustainability is the question.
IOBT generates stronger free cash flow (-18M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 21/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IO Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
IO Biotech Inc. is a clinical-stage biotechnology firm focused on pioneering innovative immunotherapy solutions to bolster the immune response against cancer. Utilizing its novel immune-oncology platform, the company aims to stimulate and enhance the body’s innate defenses to target tumor cells. With a robust pipeline of therapeutic candidates progressing through clinical trials, IO Biotech is well-positioned to meet pressing unmet needs in oncology, particularly for solid tumors. The company's dedication to rigorous scientific research underscores its potential to transform the standards of cancer treatment and significantly improve patient outcomes.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?